Table 1.
Characteristics of the studies included in the meta-analysis.
| Author | Year | Country | Time Frame | PD+VR | PD | Age | Stage | Survival Outcomes |
|---|---|---|---|---|---|---|---|---|
| Addeo P [12] | 2017 | France | 2006–2014 | 91 | 90 | PD+VR: 66 PD: 67 |
NR | Median OS 27 vs. 22 months (p = 0.28) |
| Banz VM [23] | 2011 | UK | 1997–2009 | 51 | 275 | PD+VR: 67 PD 65: |
IB: 3 (0.9%) IIA: 54 (16.6%) IIB: 268 (82.2%) IV: 1 (0.3%) |
Median OS 14.8 vs. 14.5 months (p = 0.41) |
| Chakravarty K [24] | 2010 | Taiwan | 1996–2006 | 12 | 75 | PD+VR: 62.9 PD: 62.9 |
IIA: 14 (16.1%) IIB: 3 (3.4%) |
5-year OS 16.7 vs. 12.2 (p = 0.9) |
| Cherukuru R [25] | 2018 | India | 2010–2016 | 26 | 15 | 59 * | NR | Median OS 14 vs. 17 months (p = 0.9) |
| Howard TJ [29] | 2003 | USA | NR | 13 | 23 | PD+VR: 68 PD: 67.8 |
I: 6 (16.7%) II: 9 (25%) III: 21 (58.3%) |
Median OS 12 vs. 13 months (p < 0.05) |
| Hristov B [28] | 2010 | USA | 1993–2005 | 20 | 140 | PD+VR: 63.5 PD: 54 |
NR | Median OS 20.8 vs. 21.4 months (p < 0.05) |
| Jeong J [30] | 2015 | South Korea | 1995–2009 | 46 | 230 | PD+VR: 60.5 PD: 61.5 |
NR | Median OS 16 vs. 12 months (p = 0.08) |
| Kaneoka Y [26] | 2009 | Japan | 1993–2006 | 42 | 42 | PD+VR: 66 PD: 65 |
IA: 6 (6.9%) IB: 6 (6.9%) IIA: 30 (34.5%) IIB: 38 (43.7%) III: 2 (2.3%) IV: 5 (5.7%) |
Median OS 26 vs. 12 months (p = 0.04) |
| Kelly KJ [27] | 2013 | USA | 2000–2007 | 70 | 422 | PD+VR: 66.8 PD: 65 |
NR | Median OS 19.3 vs. 15.6 months (p = 0.05) |
| Leach SD [31] | 1998 | USA | 1990–1995 | 31 | 44 | PD+VR: 66 PD: 64 |
NR | Median OS 20 vs. 22 months (p = 0.25) |
| Martin D [32] | 2018 | Switzerland | 2008–2013 | 29 | 29 | PD+VR: 69 PD: 66 |
NR | Median OS 12.9 vs. 20.3 months (p = 0.13) |
| Menon VG [33] | 2013 | USA | 2007–2012 | 18 | 43 | PD+VR: 67.2 PR: 69 |
IIB: 41 (67.2%) | Median OS 31 vs. 31 months (p = 0.9) |
| Murakami Y [34] | 2015 | Japan | 2001–2012 | 435 | 502 | 68 * | IA-I: 58 (6.2%) IIA-IIB-III-IV: 879 (93.8%) |
Median OS 18.5 vs. 25.8 months (p < 0.01) |
| Ohgi K [35] | 2017 | Japan | 2002–2014 | 158 | 141 | PD+VR: 68 PD: 67 |
NR | Median OS 20.7 vs. 18.6 months (p = 0.8) |
| Poon RT [36] | 2004 | China | 1998–2002 | 12 | 38 | PD+VR: 61.5 PD: 62.5 |
I: 17 (34%) II: 7 (14%) III: 18 (36%) IV: 8 (16%) |
Median OS 19.5 vs 20.7 months (p = 0.8) |
| Ravikumar R [37] | 2014 | UK | 1998–2011 | 230 | 840 | PD+VR: 65 PD: 66 |
NR | Median OS 18 vs. 18.2 months (p NR) |
| Roch AM [38] | 2016 | USA | 2000–2014 | 90 | 477 | PD+VR: 66.4 PD: 66.3 |
NR | Median OS 14 vs. 21 months (p = 0.08) |
| Toomey P [39] | 2009 | USA | NR | 48 | 172 | PD+VR: 67 PD: 68 |
IA: 10 (4.5%) IA: 40 (18.2%) IIA: 43 (19.6%) IIB: 127 (57.7%) |
Median OS 18 vs. 17 months (p = 0.84) |
| Turley RS [40] | 2012 | USA | 1997–2008 | 42 | 162 | PD+VR: 63.5 PD: 66 |
NR | Median OS 21 vs. 20 months (p = 0.9) |
| Wang F [41] | 2014 | Australia | 2004–2012 | 64 | 58 | PD+VR: 66 PD: 67 |
IA: 1 (0.8%) IB: 3 (2.5%) IIA: 27 (22.5%) IIB: 75 (62.5%) III: 9 (7.5%) IV: 5 (4.2%) |
Median OS 18 vs. 31 months (p = 0.02) |
| Wang WL [8] | 2015 | China | 2009–2013 | 42 | 166 | PD+VR: 59.4 PD: 60.5 |
NR | Median OS 20 vs 26 months (p = 0.2) |
| Xie ZB [42] | 2019 | China | 2011–2013 | 138 | 239 | PD+VR: 62.75 PD: 61.54 |
I: 136 (36.1%) II: 210 (55.7%) III: 31 (8.2%) |
Median OS 25.1 vs. 29.3 months (p = 0.04) |
| Zhao X [43] | 2016 | China | 2014–2016 | 21 | 85 | PD+VR: 63 PD: 63.5 |
IA: 17 (16%) IB: 18 (17%) IIA: 6 (5.7%) IIB: 65 (61.3%) |
Median OS 15 vs. 19 months (p < 0.05) |
OS: overall survival; PDAC: pancreatic ductal adenocarcinoma; NR: not reported; PD: pancreaticoduodenectomy; PD+VR: pancreaticoduodenectomy + venous resection. * Mean age was reported for the entire cohort.